
Technology Licensing & Transfer Terms
A practical diligence and contracting framework, with the intended use and ownership clearly separated.
Understand the science visually
Open any image at full size. Research pictures, original schematics and generated concepts are labelled separately; none is an Aurelia patient outcome.
What quality assessment looks at
Simplified teaching schematic; cell identity and requirements depend on the actual cell type and intended use.

Human umbilical-cord MSCs
Primary-culture morphology from different human umbilical-cord regions. A laboratory comparison, not clinical efficacy data.
Image source ↗ · Original research / source ↗
Format and display notes
保留完整画幅和原有标注,仅等比例缩小并转WebP;原始文件同时保留。
Licence know-how transfer or assignment
A licence allows agreed use while ownership remains with the rights holder. Assignment changes ownership. Know-how transfer describes the agreed practical knowledge and training; it may accompany either transaction.
Rights diligence
Inspect chain of title, relevant patents and territories, expiry, existing licences, donor or material consents, third-party restrictions and freedom to operate. A patent alone does not establish that all necessary rights are available.
Technical package
Agree cell and material specifications; manufacturing and analytical protocols; development evidence; batch records; acceptance criteria; training; deviations and change history. List exclusions and redactions as carefully as inclusions.
Quality transfer
Evaluate identity, purity, potency, sterility, traceability, batch consistency and process changes under the applicable system. Transfer analytical methods and demonstrate receiver competence; a written SOP alone is not a validated process.
Acceptance and payment structure
Define evidence-based milestones, responsibility for failed transfer, repeat work and support. Upfront, milestone, licence or royalty structures are negotiated; no prices or returns are guaranteed on this page.
Key contract conditions
Scope, field of use, territory, term, exclusivity, sublicensing, improvements, confidentiality, data rights, warranties, liability, dispute resolution and termination. Clinical and product permissions remain a separate assessment.
Current quality reference
FDA’s November 2026 final potency-assurance guidance addresses process design, material and process control, in-process testing and lot-release assays. It is guidance for a risk-based quality strategy, not a standalone certification.